Bayer's April Crucible: Legal and Financial Timelines Collide

Bayer faces a pivotal month with a Supreme Court hearing on Roundup litigation and a major settlement deadline, while maintaining its 2026 financial targets.

Bayer faces a defining month in April 2026, with a confluence of legal, financial, and shareholder events poised to shape the company's trajectory for years. The period highlights the dual pressures of ongoing litigation burdens and the company's operational resilience.

The critical sequence begins on April 27, when the U.S. Supreme Court hears arguments in a pivotal Missouri case concerning the herbicide Roundup. The case centers on whether federal law preempts state-level failure-to-warn claims, a legal argument Bayer strongly supports. A favorable ruling, expected by the end of the court's term in June, could structurally deflate the wave of future litigation. The Trump administration has backed Bayer's position, marking a reversal from the Biden-era stance.

Parallel to this high-stakes legal maneuver, Bayer is advancing a separate $7.25 billion settlement in Missouri to address existing and future claims linked to glyphosate. Claimants have until June 4, 2026, to opt out of this agreement. Since acquiring Monsanto in 2018, the company has already spent over $11 billion on settlements and judgments. The financial drain is significant: for 2026 alone, Bayer anticipates a negative free cash flow of up to €2.5 billion due to litigation payouts, with around €5 billion expected to flow out for ongoing legal disputes.

Amid these legal headwinds, the company's operational guidance remains firmly intact. Management confirms its 2026 targets, projecting currency-adjusted sales of €45 to €47 billion and an EBITDA before special items of €9.6 to €10.1 billion. This outlook notably includes the full impact of new U.S. import tariffs on pharmaceuticals. Sebastian Guth, Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer U.S., stated the 15% tariff rate for EU medicines under an existing trade framework is already factored into forecasts, mitigating the threat of potential 100% rates.

Shareholders will convene virtually for the Annual General Meeting on April 24. The agenda includes a proposed dividend of €0.11 per share for the 2025 financial year. This will be followed by the release of first-quarter 2026 figures on May 12.

The pharmaceutical division provides a core pillar of stability. The unit recorded a landmark 2025 with five new drug approvals and six positive Phase III trial results. Leadership is holding fast to its goal of lifting pharma margins to around 30% by 2030, driven by focus areas in oncology, cardiology, and women's health. Guth recently pointed to a new U.S.-U.K. pharmaceutical pact as a potential model for future global pricing negotiations.

CEO Bill Anderson has called the Supreme Court's decision to take up the case an "important step in our multi-pronged strategy to substantially contain this litigation." The coming weeks will test every facet of that strategy, balancing immediate cash flow pressures against the potential for long-term legal relief.